HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

ZNF668 Functions as a Tumor Suppressor by Regulating p53 Stability and Function in Breast Cancer

(2011) R. Hu et al.   CANCER RESEARCH

The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to Mdm2 inhibitor-mediated apoptosis

(2011) Dale Bixby et al.   CELL CYCLE

A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

(2011) J. Tabernero et al.   CLINICAL CANCER RESEARCH

Network Perspectives on HDM2 Inhibitor Chemotherapy Combinations

(2011) Asfar S. Azmi et al.   CURRENT PHARMACEUTICAL DESIGN

Degradation of MDM2 by the Interaction between Berberine and DAXX Leads to Potent Apoptosis in MDM2-Overexpressing Cancer Cells

(2010) X. Zhang et al.   CANCER RESEARCH

p53-family proteins and their regulators: hubs and spokes in tumor suppression

(2010) L Collavin et al.   CELL DEATH AND DIFFERENTIATION

Reactivation of p53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy

(2010) A.S. Azmi et al.   CURRENT CANCER DRUG TARGETS

A newly identified Pirh2 substrate SCYL1-BP1 can bind to MDM2 and accelerate MDM2 self-ubiquitination

(2010) Jing Yan et al.   FEBS LETTERS

The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias

(2010) K. Kojima et al.   MOLECULAR CANCER THERAPEUTICS

The C terminus of p53 binds the N-terminal domain of MDM2

(2010) Masha V Poyurovsky et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

A Novel Type of p53 Pathway Dysfunction in Chronic Lymphocytic Leukemia Resulting from Two Interacting Single Nucleotide Polymorphisms within the p21 Gene

(2009) G. G. Johnson et al.   CANCER RESEARCH

Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table)

(2009) G. Zauli et al.   CURRENT CANCER DRUG TARGETS

FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53

(2009) Anna Maria Ochocka et al.   FEBS LETTERS

Polo-like kinase-1 phosphorylates MDM2 at Ser260 and stimulates MDM2-mediated p53 turnover

(2009) Sylvia S. Dias et al.   FEBS LETTERS

An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals

(2009) Ramzi M Mohammad et al.   Molecular Cancer

Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions

(2009) Y.N. V. Gopal et al.   MOLECULAR CANCER THERAPEUTICS

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

(2008) Sanjeev Shangary et al.   Annual Review of Pharmacology and Toxicology

The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2–DAXX–HAUSP complex

(2008) Min Sup Song et al.   EMBO JOURNAL

Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2

(2008) J. Kitagaki et al.   MOLECULAR CANCER THERAPEUTICS

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

(2008) S. Shangary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of a novel, transactivation-defective splicing variant of p53 gene in patients with chronic lymphocytic leukemia

(2007) Sona Pekova et al.   LEUKEMIA RESEARCH